Le Lézard
Classified in: Ebola virus, Science and technology, Covid-19 virus
Subject: MRR

Global Virtual Evolved Packet Core (vEPC) Market Report 2022-2026 - Potential for Commercial 5G Services & Private 4G/5G Services to Boost Market Prospects


DUBLIN, Oct. 20, 2022 /PRNewswire/ -- The "Virtual Evolved Packet Core (vEPC) - Global Market Trajectory & Analytics" report has been added to  ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

Global Virtual Evolved Packet Core (vEPC) Market to Reach $11.8 Billion by 2026

Amid the COVID-19 crisis, the global market for Virtual Evolved Packet Core (vEPC) estimated at US$5.3 Billion in the year 2022, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 21.2% over the analysis period. 

Growth in the global market is being driven on account of several favorable factors like 5G deployments, increasing subscriber count and evolving consumer expectations. Supporting 4G LTE mobile networks, the virtual EPC framework is expected to play an important role in 5G network architecture.

The virtual EPC market is expected to be significantly bolstered by continuing developments related to 5G and increasing subscriber count for LTE services. The market growth is likely to be also facilitated by the pressing need to deliver enhanced services and efforts to measure service performance and quality. In addition, increasing adoption of machine-to-machine communication devices and the Internet of Things (IoT) technology is poised to present lucrative growth opportunities.

Virtual EPC is anticipated to benefit from rising demand for high-speed data coupled with ongoing efforts by network operators to cut operational and capital expenditure. The adoption of virtual EPC is likely to be buoyed by strong consumer demand for high-speed data for reliable connectivity and mobility.

Solutions, one of the segments analyzed in the report, is projected to grow at a 20.2% CAGR to reach US$9.6 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 23.3% CAGR for the next 7-year period.

This segment currently accounts for a 28.9% share of the global Virtual Evolved Packet Core (vEPC) market. The services segment is expected to offer the highest growth opportunities as mobile network operators continue to outsource network maintenance to vendors and avail all services associated with such contracts and concentrate on core business capabilities.

The U.S. Market is Estimated at $1.5 Billion in 2022, While China is Forecast to Reach $1.3 Billion by 2026

The Virtual Evolved Packet Core (vEPC) market in the U.S. is estimated at US$1.5 Billion in the year 2022. The country currently accounts for a 28.53% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$1.3 Billion in the year 2026 trailing a CAGR of 24.3% through the analysis period.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 19% and 19.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 19.4% CAGR while Rest of European market (as defined in the study) will reach US$1.7 Billion by the end of the analysis period.

North America is a major market for vEPC. The region was relatively slow in moving onto 4G LTE networks, but is one of the prime movers in 5G network rollouts. Moreover, the market is highly conducive for adoption of IoT services owing to the technologically advanced market conditions as well as supporting factors such as smart meters and smart homes in the region.

Growth in Asia-Pacific region is driven by the large subscriber base and continual investments in network infrastructure and management by mobile network operators. In addition, the untapped potential in the market, as well as the gradual rollout of 5G networks offers huge potential and provide the highest growth opportunities in future.

What`s New for 2022?

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS (Total 35 Featured)

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/89h9uo

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

 

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

 

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

SOURCE Research and Markets


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: